Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

BRENDA Home
show all | hide all No of entries

Information on EC 5.4.99.7 - Lanosterol synthase and Organism(s) Homo sapiens and UniProt Accession P48449

for references in articles please use BRENDA:EC5.4.99.7
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
     5 Isomerases
         5.4 Intramolecular transferases
             5.4.99 Transferring other groups
                5.4.99.7 Lanosterol synthase
Specify your search results
Select one or more organisms in this record: ?
This record set is specific for:
Homo sapiens
UNIPROT: P48449 not found.
Show additional data
Do not include text mining results
Include (text mining) results
Include results (AMENDA + additional results, but less precise)
Word Map
The taxonomic range for the selected organisms is: Homo sapiens
The expected taxonomic range for this enzyme is: Bacteria, Eukaryota
Synonyms
atlas, oxidosqualene cyclase, lanosterol synthase, 2,3-oxidosqualene cyclase, erg7p, oxidosqualene-lanosterol cyclase, 2,3-oxidosqualene-lanosterol cyclase, 2,3-oxidosqualene:lanosterol cyclase, oxidosqualene:lanosterol cyclase, squalene 2,3-oxide-lanosterol cyclase, more
SYNONYM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
lanosterol synthase
-
Oxidosqualene cyclase
-
2,3-Epoxysqualene lanosterol-cyclase
-
-
-
-
2,3-epoxysqualene--lanosterol cyclase
-
-
-
-
2,3-Epoxysqualene-lanosterol cyclase
-
-
-
-
2,3-Oxidosqualene cyclase
2,3-oxidosqualene cyclase-lanosterol synthase
-
-
2,3-Oxidosqualene sterol cyclase
-
-
-
-
2,3-Oxidosqualene-lanosterol cyclase
-
-
-
-
2,3-oxidosqualene:lanosterol cyclase
-
-
Cyclase, 2,3-oxidosqualene-lanosterol
-
-
-
-
Erg7p
-
-
hOSC
-
-
Lanosterol 2,3-oxidosqualene cyclase
-
-
-
-
lanosterol synthase
-
-
Oxidosqualene cyclase
Oxidosqualene--lanosterol cyclase
-
-
-
-
Oxidosqualene-lanosterol cyclase
oxidosqualene:lanosterol cyclase
-
-
Squalene 2,3-epoxide:lanosterol cyclase
-
-
-
-
Squalene 2,3-oxide-lanosterol cyclase
-
-
-
-
Squalene epoxidase-cyclase
-
-
-
-
Squalene-2,3-oxide-lanosterol cyclase
-
-
-
-
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
(3S)-2,3-epoxy-2,3-dihydrosqualene = lanosterol
show the reaction diagram
catalytic mechanism involving His232 via intermediates parkeol and protosta-12,24-dien-3-beta-ol, quantum mechanics/molecular mechanics, overview
-
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
cyclization
-
-
-
-
isomerization
-
-
-
-
SYSTEMATIC NAME
IUBMB Comments
(S)-2,3-Epoxysqualene mutase (cyclizing, lanosterol-forming)
-
CAS REGISTRY NUMBER
COMMENTARY hide
9032-71-7
-
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
2,3-oxidosqualene
lanosterol
show the reaction diagram
-
-
-
?
(3S)-2,3-epoxy-2,3-dihydrosqualene
lanosterol
show the reaction diagram
(3S)-2,3-epoxy-2,3-dihydrosqualene
parkeol
show the reaction diagram
-
reaction of mutant H232S
-
-
?
(3S)-2,3-epoxy-2,3-dihydrosqualene
protosta-12,24-dien-3-beta-ol
show the reaction diagram
-
reaction of mutant H232T
-
-
?
(3S)-2,3-oxidosqualene
lanosterol
show the reaction diagram
-
-
-
-
?
(S)-2,3-epoxysqualene
lanosterol
show the reaction diagram
(S)-2,3-oxidosqualene
lanosterol
show the reaction diagram
-
-
-
-
?
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
2,3-monoepoxysqualene
lanosterol
show the reaction diagram
-
-
-
-
?
2,3:22,23-diepoxysqualene
24(S),25-epoxylanosterol
show the reaction diagram
oxidosqualene
lanosterol
show the reaction diagram
-
-
-
-
?
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
2,3-oxidosqualene
lanosterol
show the reaction diagram
-
-
-
?
(3S)-2,3-epoxy-2,3-dihydrosqualene
lanosterol
show the reaction diagram
-
-
-
-
?
(3S)-2,3-oxidosqualene
lanosterol
show the reaction diagram
-
-
-
-
?
(S)-2,3-epoxysqualene
lanosterol
show the reaction diagram
-
formation of lanosterol the first sterol precursor of cholesterol in mammals
-
?
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
?
2,3-monoepoxysqualene
lanosterol
show the reaction diagram
-
-
-
-
?
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
Ro 48-8071
-
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-biphenyl-4-ylpropyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Saccharomyces cerevisiae, and Pneumocystis carinii enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-phenylpropyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Saccharomyces cerevisiae, and Pneumocystis carinii enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl hexyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Saccharomyces cerevisiae, and Pneumocystis carinii enzyme
(4-Benzenesulfonyl-piperazin-1-yl)-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
-
IC50: 143 nM
(4-bromophenyl)[4-[6-(cyclopropylmethylmethylamino)hexyloxy]phenyl]methanone
-
IC50: 31.8 nM
(4-bromophenyl)[4-[6-[(3-hydroxypropyl)methylamino]-hexyloxy]phenyl]methanone
-
IC50: 15.7 nM
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
-
(Z)-3-[4-(4-bromobenzoyl)phenacylidene]quinuclidine
-
IC50: 83 nM, oral and selective inhibition of cholesterol biosynthesis derived from enzyme inhibition
1,2-dilinoleoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
26% inhibition at 0.5 microM, no inhibition at 0.25 microM
1,2-dimyristoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
72% inhibition at 0.5 microM, 51% at 0.25 microM
1,2-dioleoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
57% inhibition at 0.5 microM, 42% at 0.25 microM
1,2-dipalmitoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
24% inhibition at 0.5 microM, 4% at 0.25 microM
1-(2-methyl-4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
IC50: 112 nM
1-(4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
IC50: 37 nM
1-linolenoyl-2-palmitoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
26% inhibition at 0.5 microM, 5% inhibition at 0.25 microM
1-linoleoyl-2-linolenoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
45% inhibition at 0.5 microM, 18% at 0.25 microM
1-linoleoyl-2-myristoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
38% inhibition at 0.5 microM, 22% at 0.25 microM
1-linoleoyl-2-oleoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
31% inhibition at 0.5 microM, 8% at 0.25 microM
1-linoleoyl-2-palmitoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
27% inhibition at 0.5 microM, 3% at 0.25 microM
1-myristoyl-2-palmitoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
45% inhibition at 0.5 microM, 35% at 0.25 microM
1-oleoyl-2-linolenoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
29% inhibition at 0.5 microM, 7% at 0.25 microM
1-oleoyl-2-linoleoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
40% inhibition at 0.5 microM, 9% at 0.25 microM
1-oleoyl-2-palmitoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
46% inhibition at 0.5 microM, 24% at 0.25 microM
1-palmitoyl-2-linoleoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
20% inhibition at 0.5 microM, no inhibition at 0.25 microM
1-palmitoyl-2-oleoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
21% inhibition at 0.5 microM, 4% at 0.25 microM
1-[4-(trifluoromethoxy)phenylcarbonyl]-4-[4-(dimethylaminomethyl)phenylmeth yl]-piperazine
-
-
1-[4-chlorobenzyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylcarbonyl]-4-[4-(1-methyl-pyrazol-4-yl)phenylmethyl]-piperazine
-
inactive at 200 nM
1-[4-chlorophenylcarbonyl]-4-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenylmethyl]-piperazine
-
inactive at 200 nM
1-[4-chlorophenylcarbonyl]-4-[4-(dimethylaminomethyl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylcarbonyl]-4-[4-(imidazol-1-yl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylcarbonyl]-4-[4-(pyrazol-1-yl)phenylmethyl]-piperazine
-
inactive at 200 nM
1-[4-chlorophenylcarbonyl]-4-[4-(pyrazol-3-yl)phenylmethyl]-piperazine
-
inactive at 200 nM
1-[4-chlorophenylcarbonyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylsulfonyl]-4-[3-(pyridin-4-yl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylsulfonyl]-4-[4-(4-methylpiperazin-1-yl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylsulfonyl]-4-[4-(dimethylaminomethyl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylsulfonyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
-
-
1-[4-methoxyphenylcarbonyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
-
-
1-[4-trifluoroacetyl]-4-[4-(imidazol-1-yl)phenylmethyl]-piperazine
-
inactive at 200 nM
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide
-
-
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide N-oxide
-
-
3-[(4-chlorobenzoyl)-4-phenoxy]quinuclidin-3-ol
-
-
3-[(4-chlorobenzoyl)-4-phenoxy]quinuclidine
-
-
3-[2-(4-bromobenzophenone)ethynyl]quinuclidin-3-ol
-
-
3beta-(2-diethylaminoethoxy)androst-5-en-17-one hydrochloride
-
U18666A
4-chloro-N-(4-{4-[(dimethylamino)methyl]phenyl}cyclohexyl)-N-methylbenzamide
-
BIBX 79
allyl-6-[4-(4-bromophenyl)-1H-benzo[d][1,2]oxazin-7-yloxy]hexylmethylamine
-
IC50: 4.1 nM
allyl[6-[1-(4-bromophenyl)-3,4-dihydroisoquinolin-6-yloxy]hexyl]methylamine
-
IC50: 7.9 nM
allyl[6-[1-(4-bromophenyl)isoquinolin-6-yloxy]hexyl]methylamine
-
IC50: 3.5 nM
allyl[6-[3-(4-bromophenyl)-1-methyl-1H-indazol-6-yloxy]hexyl]methylamine
-
IC50: 19.6 nM
allyl[6-[3-(4-bromophenyl)benzo[b]thiophen-6-yloxy]hexyl]methylamine
-
IC50: 5.6 nM
allyl[6-[3-(4-bromophenyl)benzo[d]isothiazol-6-yloxy]hexyl]methylamine
-
IC50: 2.9 nM
allyl[6-[4-(4-bromophenyl)-2H-chromen-7-yloxy]hexyl]methylamine
-
IC50: 11.4 nM
allyl[6-[4-(4-bromophenyl)quinazolin-7-yloxy]hexyl]methylamine
-
IC50: 12.3 nM
allyl[6-[4-(6-bromo-1,1-dioxobenzo[d]isothiazol-3-yl)phenoxy]hexyl]methylamine
-
IC50: 7.8 nM
BIBB 515
-
-
dehydrocostus lactone
-
isolated from Laurus nobilis extract, 22% inhibition at 0.25 mM, 63% inhibition at 0.5 mM
eremanthine
-
isolated from Laurus nobilis extract, 12% inhibition at 0.25 mM, 70% inhibition at 0.5 mM
ethanol extract from Angelica keiskei leaves
-
11% inhibition at 0.3 mg/ml
-
ethanol extract from Basella rubra leaves
-
5% inhibition at 0.3 mg/ml
-
ethanol extract from Chrysanthemum morifolium flowers
-
13% inhibition at 0.3 mg/ml
-
ethanol extract from Chrysanthemum morifolium leaves
-
7% inhibition at 0.3 mg/ml
-
ethanol extract from Colocasia esculenta rhizomes
-
55% inhibition at 0.3 mg/ml
-
ethanol extract from Cryptotaenia japonica leaves
-
10% inhibition at 0.3 mg/ml
-
ethanol extract from Glycine max immature seeds
-
14% inhibition at 0.3 mg/ml
-
ethanol extract from Oenanthe stolonifera leaves
-
13% inhibition at 0.3 mg/ml
-
ethanol extract from Perilla frutescens leaves
-
5% inhibition at 0.3 mg/ml
-
ethanol extract from Petasites japonicus buds
-
6% inhibition at 0.3 mg/ml
-
ethanol extract from Zingiber officinale buds
-
14% inhibition at 0.3 mg/ml
-
ethanol extract from Zingiber officinale rhizomes
-
6% inhibition at 0.3 mg/ml
-
N-[2-(4-(3-dimethylaminomethylphenyl)phenyl)ethyl]-4-cyanobenzenesulfonamide
-
inactive at 200 nM
N-[2-(4-(4-((pyrrolidin-1-yl)methyl)phenyl)phenyl)ethyl]-4-chlorobenzenesulfonamide
-
-
N-[2-(4-(4-dimethylaminomethylphenyl)phenyl)ethyl]-4-cyanobenzenesulfonamide
-
-
Ro 48-8071
-
IC50: 8.0 nM for the recombinant enzyme, IC50: 6.5 nM for the human liver enzyme
Ro48-8071
-
-
S23515
-
-
trans-N-(4-(5-[ethyl-(2-hydroxy-ethyl)-amino]-pentyl)-cyclohexyl)-N-methyl-4-trifluoromethyl-benzenesulfonamide fumarate
-
RO0714565
U18666A
-
-
ZD-9720
-
-
[4'-(6-allyl-methyl-amino-hexyloxy)-2'-fluoro-phenyl]-(4-bromo-phenyl)-methanone fumarate
-
RO0488071
[4'-(6-allyl-methyl-amino-hexyloxy)-2'-fluoro-phenyl]-(4-bromophenyl)-methanone fumarate
-
Ro 48-8071
[4-(4-Bromo-benzenesulfonyl)-piperazin-1-yl]-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
-
IC50: 161 nM
[4-[6-(allylmethylamino)hexyloxy]-2-hydroxyphenyl](4-bromophenyl)methanone
-
IC50: 6.3 nM
[4-[6-(allylmethylamino)hexyloxy]-2-methoxyphenyl](4-bromophenyl)methanone
-
IC50: 4.6 nM
[4-[6-(allylmethylamino)hexyloxy]-2-methylaminophenyl](4-bromophenyl)methanone
-
IC50: 4.1 nM
[4-[6-(allylmethylamino)hexyloxy]-2-methylsulfanylphenyl](4-bromophenyl)methanone
-
IC50: 6.2 nM
[4-[6-(allylmethylamino)hexyloxy]phenyl](4-bromophenol)methanone
-
IC50: 5.4 nM
[4-[6-(allylmethylamino)hexyloxy]phenyl](4-nitrophenyl)methanone
-
IC50: 1.9 nM
[4-[6-(allylmethylamino)hexyloxy]phenyl]-(4-fluorophenyl)methanone
-
IC50: 6.7 nM
[4-[6-(allylmethylamino)hexyloxy]phenyl]phenylmethanone
-
IC50: 22.5 nM
[6-[6-(allylmethylamino)hexyloxy]pyridin-3-yl](4-bromophenyl)methanone
-
IC50: 8.7 nM
[6-[6-(cyclopropylmethylamino)hexyloxy]phenyl](4-bromophenyl)methanone
-
IC50: 35.3 nM
additional information
-
3-alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl-sn-glycerol has no inhibitory effect
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
Rat liver cytosol carrier protein
-
enhances lanosterol synthase activity in placental microsomes
additional information
-
no protective action of steroid-3-ketoreductase towards OSC is necessary
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0045
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-biphenyl-4-ylpropyl ether
Homo sapiens
-
-
0.0011
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-phenylpropyl ether
Homo sapiens
-
-
0.00085
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl hexyl ether
Homo sapiens
-
-
0.000143
(4-Benzenesulfonyl-piperazin-1-yl)-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
Homo sapiens
-
IC50: 143 nM
0.0000318
(4-bromophenyl)[4-[6-(cyclopropylmethylmethylamino)hexyloxy]phenyl]methanone
Homo sapiens
-
IC50: 31.8 nM
0.0000157
(4-bromophenyl)[4-[6-[(3-hydroxypropyl)methylamino]-hexyloxy]phenyl]methanone
Homo sapiens
-
IC50: 15.7 nM
0.000083
(Z)-3-[4-(4-bromobenzoyl)phenacylidene]quinuclidine
Homo sapiens
-
IC50: 83 nM, oral and selective inhibition of cholesterol biosynthesis derived from enzyme inhibition
0.000112
1-(2-methyl-4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
Homo sapiens
-
IC50: 112 nM
0.000037
1-(4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
Homo sapiens
-
IC50: 37 nM
0.00002
1-[4-(trifluoromethoxy)phenylcarbonyl]-4-[4-(dimethylaminomethyl)phenylmeth yl]-piperazine
Homo sapiens
-
-
0.000316
1-[4-chlorobenzyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.0002
1-[4-chlorophenylcarbonyl]-4-[4-(1-methyl-pyrazol-4-yl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.0002
1-[4-chlorophenylcarbonyl]-4-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.00004
1-[4-chlorophenylcarbonyl]-4-[4-(dimethylaminomethyl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.000032
1-[4-chlorophenylcarbonyl]-4-[4-(imidazol-1-yl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.0002
1-[4-chlorophenylcarbonyl]-4-[4-(pyrazol-1-yl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.0002
1-[4-chlorophenylcarbonyl]-4-[4-(pyrazol-3-yl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.000003
1-[4-chlorophenylcarbonyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.0005
1-[4-chlorophenylsulfonyl]-4-[3-(pyridin-4-yl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.000006
1-[4-chlorophenylsulfonyl]-4-[4-(4-methylpiperazin-1-yl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.000032
1-[4-chlorophenylsulfonyl]-4-[4-(dimethylaminomethyl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.000013
1-[4-chlorophenylsulfonyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.002511
1-[4-methoxyphenylcarbonyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.0002
1-[4-trifluoroacetyl]-4-[4-(imidazol-1-yl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.0000041
allyl-6-[4-(4-bromophenyl)-1H-benzo[d][1,2]oxazin-7-yloxy]hexylmethylamine
Homo sapiens
-
IC50: 4.1 nM
0.0000079
allyl[6-[1-(4-bromophenyl)-3,4-dihydroisoquinolin-6-yloxy]hexyl]methylamine
Homo sapiens
-
IC50: 7.9 nM
0.0000035
allyl[6-[1-(4-bromophenyl)isoquinolin-6-yloxy]hexyl]methylamine
Homo sapiens
-
IC50: 3.5 nM
0.0000196
allyl[6-[3-(4-bromophenyl)-1-methyl-1H-indazol-6-yloxy]hexyl]methylamine
Homo sapiens
-
IC50: 19.6 nM
0.0000056
allyl[6-[3-(4-bromophenyl)benzo[b]thiophen-6-yloxy]hexyl]methylamine
Homo sapiens
-
IC50: 5.6 nM
0.0000029
allyl[6-[3-(4-bromophenyl)benzo[d]isothiazol-6-yloxy]hexyl]methylamine
Homo sapiens
-
IC50: 2.9 nM
0.0000114
allyl[6-[4-(4-bromophenyl)-2H-chromen-7-yloxy]hexyl]methylamine
Homo sapiens
-
IC50: 11.4 nM
0.0000123
allyl[6-[4-(4-bromophenyl)quinazolin-7-yloxy]hexyl]methylamine
Homo sapiens
-
IC50: 12.3 nM
0.0000078
allyl[6-[4-(6-bromo-1,1-dioxobenzo[d]isothiazol-3-yl)phenoxy]hexyl]methylamine
Homo sapiens
-
IC50: 7.8 nM
0.00000585
BIBB 515
Homo sapiens
-
-
0.0002
N-[2-(4-(3-dimethylaminomethylphenyl)phenyl)ethyl]-4-cyanobenzenesulfonamide
Homo sapiens
-
-
0.000063
N-[2-(4-(4-((pyrrolidin-1-yl)methyl)phenyl)phenyl)ethyl]-4-chlorobenzenesulfonamide
Homo sapiens
-
-
0.000028
N-[2-(4-(4-dimethylaminomethylphenyl)phenyl)ethyl]-4-cyanobenzenesulfonamide
Homo sapiens
-
-
0.0000065 - 0.000008
Ro 48-8071
0.000161
[4-(4-Bromo-benzenesulfonyl)-piperazin-1-yl]-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
Homo sapiens
-
IC50: 161 nM
0.0000063
[4-[6-(allylmethylamino)hexyloxy]-2-hydroxyphenyl](4-bromophenyl)methanone
Homo sapiens
-
IC50: 6.3 nM
0.0000046
[4-[6-(allylmethylamino)hexyloxy]-2-methoxyphenyl](4-bromophenyl)methanone
Homo sapiens
-
IC50: 4.6 nM
0.0000041
[4-[6-(allylmethylamino)hexyloxy]-2-methylaminophenyl](4-bromophenyl)methanone
Homo sapiens
-
IC50: 4.1 nM
0.0000062
[4-[6-(allylmethylamino)hexyloxy]-2-methylsulfanylphenyl](4-bromophenyl)methanone
Homo sapiens
-
IC50: 6.2 nM
0.0000054
[4-[6-(allylmethylamino)hexyloxy]phenyl](4-bromophenol)methanone
Homo sapiens
-
IC50: 5.4 nM
0.0000019
[4-[6-(allylmethylamino)hexyloxy]phenyl](4-nitrophenyl)methanone
Homo sapiens
-
IC50: 1.9 nM
0.0000067
[4-[6-(allylmethylamino)hexyloxy]phenyl]-(4-fluorophenyl)methanone
Homo sapiens
-
IC50: 6.7 nM
0.0000225
[4-[6-(allylmethylamino)hexyloxy]phenyl]phenylmethanone
Homo sapiens
-
IC50: 22.5 nM
0.0000087
[6-[6-(allylmethylamino)hexyloxy]pyridin-3-yl](4-bromophenyl)methanone
Homo sapiens
-
IC50: 8.7 nM
0.0000353
[6-[6-(cyclopropylmethylamino)hexyloxy]phenyl](4-bromophenyl)methanone
Homo sapiens
-
IC50: 35.3 nM
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
Uniprot
Manually annotated by BRENDA team
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
-
monotopic, integral membrane protein
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
metabolism
-
oxidosqualene-lanosterol cyclase is a key enzyme in the biosynthesis of cholesterol
additional information
-
H232 mutant energy profiles compared to the wild-type enzyme, overview
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION?
LSS_HUMAN
732
0
83309
Swiss-Prot
other Location (Reliability: 3)
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
80000
-
1 * 80000, SDS-PAGE
86000
-
equilibrium sedimentation
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
monomer
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
additional information
-
the protein is neither glycosylated nor modified post-translationally
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
hanging-drop vapor-diffusion method
-
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
H232S
-
site-directed mutagenesis, mutant energy profile compared to the wild-type enzyme
H232T
-
site-directed mutagenesis, mutant energy profile compared to the wild-type enzyme
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
-80°C, 10% glycerol, stable for at least 1 year
-
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
expression in Pichia pastoris
-
expression in Saccharomyces cerevisiae
-
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
drug development
the enzyme represents a target for the discovery of novel anticholesteraemic drugs
drug development
-
the enzyme represents a novel target for treatment of hypercholesterolemia and atherosclerosis
medicine
nutrition
-
since lanosterol synthase is located in the middle stage of the biosynthetic pathway of cholesterol in mammals, it may be important to know the acyl composition of digalactosyl diacylglycerol in vegetables for evaluating the efficacy of them against hypercholesterolemia
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Tabacik, C.; Descomps, B.; Crastles de Paulet, A.
The squalene epoxide-cyclase activity of human term placenta
FEBS Lett.
34
238-242
1973
Homo sapiens
Manually annotated by BRENDA team
Viola, F.; Brusa, P.; Balliano, G.; Ceruti, M.; Boutaud, O.; Schuber, F.; Cattel, L.
Inhibition of 2,3-oxidosqualene cyclase and sterol biosynthesis by 10- and 19-azasqualene derivatives
Biochem. Pharmacol.
50
787-796
1995
Saccharomyces cerevisiae, Candida albicans, Homo sapiens, Rattus norvegicus, Sus scrofa
Manually annotated by BRENDA team
Ruf, A.; Muller, F.; D'Arcy, B.; Stihle, M.; Kusznir, E.; Handschin, C.; Morand, O.H.; Thoma, R.
The monotopic membrane protein human oxidosqualene cyclase is active as monomer
Biochem. Biophys. Res. Commun.
315
247-254
2004
Homo sapiens
Manually annotated by BRENDA team
Brown, G.R.; Hollinshead, D.M.; Stokes, E.S.; Clarke, D.S.; Eakin, M.A.; Foubister, A.J.; Glossop, S.C.; Griffiths, D.; Johnson, M.C.; McTaggart, F.; Mirrlees, D.J.; Smith, G.J.; Wood, R.
Quinuclidine inhibitors of 2,3-oxidosqualene cyclase-lanosterol synthase: optimization from lipid profiles
J. Med. Chem.
42
1306-1311
1999
Homo sapiens, Rattus norvegicus
Manually annotated by BRENDA team
Brown, G.R.; Hollinshead, D.M.; Stokes, E.S.; Waterson, D.; Clarke, D.S.; Foubister, A.J.; Glossop, S.C.; McTaggart, F.; Mirrlees, D.J.; Smith, G.J.; Wood, R.
A novel series of 4-piperidinopyridine and 4-piperidinopyrimidine inhibitors of 2,3-oxidosqualene cyclase-lanosterol synthase
J. Med. Chem.
43
4964-4972
2000
Homo sapiens, Rattus norvegicus
Manually annotated by BRENDA team
Dehmlow, H.; Aebi, J.D.; Jolidon, S.; Ji, Y.H.; von der Mark, E.M.; Himber, J.; Morand, O.H.
Synthesis and structure-activity studies of novel orally active non-terpenoic 2,3-oxidosqualene cyclase inhibitors
J. Med. Chem.
46
3354-3370
2003
Homo sapiens
Manually annotated by BRENDA team
Venteclef, N.; Guillard, R.; Issandou, M.
The imidazoline-like drug S23515 affects lipid metabolism in hepatocyte by inhibiting the oxidosqualene: lanosterol cyclase activity
Biochem. Pharmacol.
69
1041-1048
2005
Macaca fascicularis, Homo sapiens, Rattus norvegicus
Manually annotated by BRENDA team
Sakano, Y.; Mutsuga, M.; Tanaka, R.; Suganuma, H.; Inakuma, T.; Toyoda, M.; Goda, Y.; Shibuya, M.; Ebizuka, Y.
Inhibition of human lanosterol synthase by the constituents of Colocasia esculenta (taro)
Biol. Pharm. Bull.
28
299-304
2005
Homo sapiens
Manually annotated by BRENDA team
Tanaka, R.; Sakano, Y.; Nagatsu, A.; Shibuya, M.; Ebizuka, Y.; Goda, Y.
Synthesis of digalactosyl diacylglycerols and their structure-inhibitory activity on human lanosterol synthase
Bioorg. Med. Chem. Lett.
15
159-162
2005
Homo sapiens
Manually annotated by BRENDA team
Thoma, R.; Schulz-Gasch, T.; D'Arcy, B.; Benz, J.; Aebi, J.; Dehmlow, H.; Hennig, M.; Stihle, M.; Ruf, A.
Insight into steroid scaffold formation from the structure of human oxidosqualene cyclase
Nature
432
118-122
2004
Homo sapiens (P48449), Homo sapiens
Manually annotated by BRENDA team
Huff, M.W.; Telford, D.E.
Lord of the rings--the mechanism for oxidosqualene:lanosterol cyclase becomes crystal clear
Trends Pharmacol. Sci.
26
335-340
2005
Homo sapiens, Sus scrofa
Manually annotated by BRENDA team
Galli, U.; Oliaro-Bosso, S.; Taramino, S.; Venegoni, S.; Pastore, E.; Tron, G.C.; Balliano, G.; Viola, F.; Sorba, G.
Design, synthesis, and biological evaluation of new (2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-ol ethers as inhibitors of human and Trypanosoma cruzi oxidosqualene cyclase
Bioorg. Med. Chem. Lett.
17
220-224
2007
Saccharomyces cerevisiae, Homo sapiens, Pneumocystis carinii, Trypanosoma cruzi
Manually annotated by BRENDA team
Tanaka, R.; Sakano, Y.; Shimizu, K.; Shibuya, M.; Ebizuka, Y.; Goda, Y.
Constituents of Laurus nobilis L. inhibit recombinant human lanosterol synthase
J. Nat. Med.
60
78-81
2006
Homo sapiens
-
Manually annotated by BRENDA team
Fouchet, M.H.; Donche, F.; Martin, C.; Bouillot, A.; Junot, C.; Boullay, A.B.; Potvain, F.; Magny, S.D.; Coste, H.; Walker, M.; Issandou, M.; Dodic, N.
Design and evaluation of a novel series of 2,3-oxidosqualene cyclase inhibitors with low systemic exposure, relationship between pharmacokinetic properties and ocular toxicity
Bioorg. Med. Chem.
16
6218-6232
2008
Homo sapiens
Manually annotated by BRENDA team
Duniec-Dmuchowski, Z.; Fang, H.L.; Strom, S.C.; Ellis, E.; Runge-Morris, M.; Kocarek, T.A.
Human pregnane X receptor activation and CYP3A4/CYP2B6 induction by 2,3-oxidosqualene:lanosterol cyclase inhibition
Drug Metab. Dispos.
37
900-908
2009
Homo sapiens
Manually annotated by BRENDA team
Taramino, S.; Teske, B.; Oliaro-Bosso, S.; Bard, M.; Balliano, G.
Divergent interactions involving the oxidosqualene cyclase and the steroid-3-ketoreductase in the sterol biosynthetic pathway of mammals and yeasts
Biochim. Biophys. Acta
1801
1232-1237
2010
Saccharomyces cerevisiae, Homo sapiens, Saccharomyces cerevisiae SCY876 and BTY6-5-3
Manually annotated by BRENDA team
Tian, B.X.; Eriksson, L.A.
Catalytic mechanism and product specificity of oxidosqualene-lanosterol cyclase: a QM/MM study
J. Phys. Chem. B
116
13857-13862
2012
Homo sapiens
Manually annotated by BRENDA team